Carpe Diem

Tag: Zenkuda

Kodiak Sciences KOD FunStock dashboard tracking institutional ownership, short interest, financials and Phase 3 biotech results.

Kodiak Sciences (KOD): Why the FunStock Gauges Keep Running After You Buy

Kodiak Sciences was around $26 when we published our cautiously bullish analysis after Baker Bros. made a major investment. Nine months later, KOD closed at $89.92 after successful Phase 3 results. But the bigger lesson may be what the FunStock gauges revealed along the way.

Read entire article

Tags: Baker Bros Advisors, Baker Brothers, biotech investing, biotech stocks, Carpe Diem, FDA approval, FunStock, FunStock Method, growth stocks, hedge funds, insider investing, institutional ownership, investment research, KOD, KOD stock, Kodiak Sciences, Kodiak Sciences stock, KSI-501, Phase 3 clinical trials, retinal disease, short interest, short squeeze, speculative investing, tabirafusp-ted, wet AMD, Zenkuda